Kestra Private Wealth Services LLC Raises Position in Novo Nordisk A/S (NYSE:NVO)

Kestra Private Wealth Services LLC increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 22.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 59,531 shares of the company's stock after purchasing an additional 10,891 shares during the quarter. Kestra Private Wealth Services LLC's holdings in Novo Nordisk A/S were worth $4,134,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Formidable Asset Management LLC boosted its holdings in Novo Nordisk A/S by 9.4% in the 1st quarter. Formidable Asset Management LLC now owns 15,948 shares of the company's stock valued at $1,107,000 after purchasing an additional 1,372 shares during the period. Auxano Advisors LLC increased its stake in shares of Novo Nordisk A/S by 29.4% in the first quarter. Auxano Advisors LLC now owns 39,392 shares of the company's stock valued at $2,735,000 after buying an additional 8,949 shares during the period. Outfitter Financial LLC lifted its holdings in shares of Novo Nordisk A/S by 32.0% during the first quarter. Outfitter Financial LLC now owns 11,610 shares of the company's stock worth $806,000 after purchasing an additional 2,815 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Novo Nordisk A/S by 9,521.4% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 343,389 shares of the company's stock worth $24,219,000 after purchasing an additional 339,820 shares during the last quarter. Finally, Creekmur Asset Management LLC increased its holdings in Novo Nordisk A/S by 784.5% in the first quarter. Creekmur Asset Management LLC now owns 9,031 shares of the company's stock valued at $627,000 after purchasing an additional 8,010 shares during the period. Institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Price Performance

NVO traded up $0.65 during trading on Monday, reaching $64.96. 8,269,314 shares of the stock were exchanged, compared to its average volume of 7,379,832. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $139.74. The business's 50 day moving average price is $70.34 and its two-hundred day moving average price is $74.21. The company has a market capitalization of $290.05 billion, a price-to-earnings ratio of 19.03, a P/E/G ratio of 1.24 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion for the quarter. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.